
What next for troubled Nottingham NHS trust after £1.6m fine?
The details of the case
Adele O'Sullivan died on 7 April 2021 - just 26 minutes old - Kahlani Rawson died on 15 June at four days old and Quinn Lias Parker died on 16 July at two days old. NUH pleaded guilty to six counts of failing to provide safe care and treatment to the babies and their mothers, in a prosecution brought by the healthcare watchdog, the Care Quality Commission (CQC). The court heard there were similar failings in all three cases, including a failure to expedite the delivery of the babies, not recognising serious conditions, communication issues and staff not being equipped to interpret anomalies in foetal heart monitoring. It was the second time the trust had been prosecuted by the CQC for maternity failings.
In 2023, the trust was fined £800,000 over the death of Wynter Andrews, who died shortly after her birth at the Queen's Medical Centre in 2019. Until this year, that fine was the largest handed down for maternity failings. NUH prosecutions make up two of five maternity-related criminal prosecutions brought by the CQC. The watchdog gained powers under the Health and Social Care Act 2008 (Regulated activities) Regulations 2014, in 2015.This prosecution by the CQC is separate from any prosecution that could arise from a corporate manslaughter investigation, which was opened earlier this month.On 2 June, Nottinghamshire Police said it was examining whether maternity care provided by NUH had been grossly negligent.
How did the judge decide on £1.6m?
In her sentencing remarks, District Judge Grace Leong said she would have to fix a "significant financial penalty" to mark the gravity of the offences, but also had to strike "a delicate balance"."I cannot ignore the negative impact that the fine will have on services to patients at a time when the NHS continues to face unprecedented challenges both in terms of insufficient funding, the backlog of patients waiting for treatment and the demands placed upon the trust's services from an ageing population," the judge said.There was no ceiling to the level of fine the judge could impose.That meant the sentence was a matter of discretion, with the judge considering other sources of guidance - such as any High Court or Court of Appeal judgements - and other sentencing guidelines for comparable offences.It was reduced from a starting point of £5.5m, as the judge took into account the financial implications on the public body and its guilty pleas.
How could the fine impact services?
In response to the BBC, a statement from NUH chief executive Anthony May said: "We fully accept the findings from court, including the fine handed down by the judge. "The mothers and families of these babies have had to endure things that no family should after the care provided by our hospitals failed them, and for that I am truly sorry."We will work to ensure to minimise the impact of the fine on our patients, including ongoing efforts to improve our maternity services."NUH did not want to put anyone forward for interview, and did not wish to detail how the fine might impact services.
Roy Lilley, former chairman of the old Homewood NHS Trust in Chertsey, Surrey - which later merged with Ashford and St. Peter's Hospitals NHS Trust - and now an independent commentator on health service issues, said some impact on services would be "inevitable". "Clearly a chunk of money like £1.6m is going to have an impact on the trust's ability to operate."The day-to-day running of the trust is, of course, difficult enough with all the financial pressures but to have this kind of money taken out of its revenue balances, it makes it even more difficult," he said. Mr Lilley - who has not worked for NUH - added: "It will certainly slow down some of the plans that they had in terms of improvements.""Generally it has a very bad effect, a big impact on the trust's ability to respond," he said. Mr Lilley said it was possible for trusts to seek loans from the Department of Health of Social Care (DHSC) in the face of financial difficulty. The BBC understands while NHS trusts are expected to meet their legal and financial obligations - including prosecution fines - they can access loans in some instances. The trust's annual budget is £1.8bn.
What does the fine mean to the families?
The families affected by NUH's maternity failings have consistently called for accountability.Following the sentencing, solicitor Natalie Cosgrave - representing the parents of baby Quinn - said in a statement that the prosecution was "the only system that exists" to obtain it.Sadie Simpson, an associate clinical negligence solicitor who represented the families of Adele and Kahlani, told the BBC the trust's guilty plea was "some level of accountability, but it's only one part of a much bigger picture".To the bereaved families, it is individuals who should be held accountable, not just the trust as an organisation, Ms Simpson said.Ms Simpson has also represented the families of Adele and Kahlani, as well as others, in civil claims against NUH. At each stage of the various investigations and proceedings they have endured - including inquests, internal reviews and court hearings - the families have called for more change and scrutiny. Ms Simpson said: "The judge was very clear that a fine is the only sentence that she can impose, and no fine is ever going to be enough when you've lost your child."
During the sentencing in February, the earlier case of Wynter Andrews - who died 23 minutes after being born - was referenced several times.Her parents Sarah and Gary Andrews watched the hearing from the public gallery "as concerned parents", but did not know their daughter's case would be mentioned "quite so prominently". "I think for us it's important to highlight that this process is the only avenue that families have to get some accountability," he said."The judge is in a really difficult position, I feel, but we're counting pennies over babies' lives."
Where does the money go?
The fine is paid to HM Treasury - the government's finance ministry which controls public spending - as with any prosecution fine.Families affected in this case will not receive any of the money from the prosecution.The trust was also told to cover prosecution costs of £67,755.23 and a victim surcharge of £190.Prosecution costs in this case will be paid to the CQC. The victim surcharge - which is imposed on offenders to ensure they hold some responsibility towards the cost of support victims and witnesses - goes to a general fund and not directly to those involved. That money provides a contribution towards Ministry of Justice-funded support services for victims and witnesses. The £1.6m fine is separate from the tens of millions of pounds the trust has paid out in damages for civil claims in relation to maternity care.
What next for the trust?
Nottinghamshire Police's investigation into the trust's maternity services - called Operation Perth - has seen more than 200 family cases referred to it so far.Meanwhile, the separate maternity review by senior midwife Donna Ockenden is currently examining the testimony of more than 2,000 cases. The review began in September 2022 and closed to new cases at the end of May. Ms Ockenden's final report of findings is due to be published in June 2026.And last week, the trust announced plans to cut at least 430 jobs in an attempt to save £97m in the next year.The planned job cuts follow the government's instruction to all trusts to reduce the size of their corporate and support services, and were not as a result of the record fine, the trust said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

South Wales Argus
3 hours ago
- South Wales Argus
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'


Daily Mail
3 hours ago
- Daily Mail
I'm a doctor - this one household feature is slowly harming your health
A common household feature may be unknowingly creating an unseen health risk – and it's hiding in plain sight. According to GP Dr Emily Carter, older carpets pose an unexpected health threat. 'People usually think of carpets as harmless,' said Dr Carter. 'But old carpets can be a major source of indoor pollution.' Carpets are known to trap allergens like dust mites, pet dander, pollen, mould spores, and even chemical residues from cleaning products or smoke. Over time, these build up in the fibres and can trigger or worsen health issues especially in children, the elderly, and those with asthma or allergies. The difficulty is that this build-up can occur gradually - even when older carpet is regularly vacuumed or appears clean. There are certain recurring health symptoms to be on the look out for that may indicate that your home environment could be be impacting on your health. Signs include frequent sneezing, coughing, or itchy eyes while indoors, worsening allergy or asthma symptoms. Feeling tired or headachy without clear cause is another indicator. Sudden skin irritations - especially in younger children – can also result from carpet-trapped allergens. However, the tricky part with many of these symptoms is that many may be mistaken for seasonal allergies or minor colds. Dr Carter, who is also a UK-based mother of two young children, said she had seen first-hand the health issues that can be caused by older carpets. 'I've seen it in my own family, my youngest started getting skin rashes and breathing problems that we couldn't explain,' Dr Carter said. 'After having our carpets replaced and testing air quality, the symptoms started improving.' For anyone who is concerned about whether their carpet poses a possible health risk, the British doctor recommends a simple 'sniff test' as a first line assessment. 'If a room smells musty no matter how often you clean it, that's a red flag,' Dr Carter said. 'Especially in bedrooms, where people spend hours each night, clean air matters more than we think.' For families with babies, Dr Carter also urges extra caution: 'Young children spend a lot of time crawling and playing on floors.' 'Their immune systems are still developing, so they're more likely to react to mould spores and dust mites. If you notice frequent eczema flare-ups or a child often gets congested indoors, your flooring could be part of the problem.' According to My Home Improvements, most carpets should be replaced every 7–10 years, depending on usage, cleaning habits, and exposure to pets or dampness. The UK home renovation business suggests that any carpet over a decade old is likely to be 'past its best'. 'Your carpet is like a sponge, it absorbs everything that enters your home. Over time, it collects years of grime, allergens, and chemical residues that vacuuming can't always reach,' says an expert from My Home Improvements. 'Even professional deep cleans won't remove built-up toxins that have soaked into the padding underneath. 'Replacing old flooring might not be glamorous, but it could be the biggest upgrade you make for your health.'

Rhyl Journal
3 hours ago
- Rhyl Journal
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'